RxDoctor Payments Data

Li Voepel, MD

Physical Medicine & Rehabilitation · Melbourne, FLNPI 1144294596

Payments from drug & device makers

$302in general payments, 2019–2025

Across 18 payments — averaging $16.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$59
  • AbbVie$57
  • Zimmer Biomet$28
  • Stryker$24
  • Biodelivery Sciences International, Inc.$24
  • Orthogenrx Inc.$21
  • plus $88 from 6 others

What the payments were for

  • Food & beverage$302100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer4$59
AbbVie3$57
Zimmer Biomet1$28
Stryker1$24
Biodelivery Sciences International, Inc.2$24
Orthogenrx Inc.1$21
Sanofi-aventis U.S. LLC1$18
Collegium Pharmaceutical, Inc.1$18
Amgen1$17
Scilex Pharmaceuticals Inc.1$17
Abbott1$16
Electronic Waveform Lab, Inc.1$3

How this compares

$302 in reported general payments places this provider in the 55th percentile of 618 physical medicine & rehabilitation providers in Florida.

See all physical medicine & rehabilitation providers in Florida

Medicare billing

Part B allowed, 2024
$439,159
Medicare patients
141
Services billed
48,617

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen298$6,614
Xtampza ErOxycodone Myristate14$6,447
Fentanyl60$5,763
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen185$3,384
Oxycodone Hcl232$2,956
Gabapentin251$2,636
Celecoxib133$1,835
Morphine Sulfate ErMorphine Sulfate57$1,590
Methocarbamol79$1,509
Tramadol Hcl212$1,382
Pregabalin101$1,363
Lidocaine11$1,319
Eszopiclone63$949
Duloxetine Hcl27$704
Cyclobenzaprine Hcl135$696

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$18$6,44714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 618 physical medicine & rehabilitation providers in Florida.

Other physical medicine & rehabilitation in Melbourne

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →